Dalia Ercan
Moffitt Cancer Center · 187 works · 9,046 citations · h-index 23
Top works
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
- Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- Pharmacological targeting of the pseudokinase Her3
- Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
- Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
- Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET